Meningococcal (groups A, C, Y and W-135) oligosaccharide diphtheria CRM197 conjugate vaccine

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Meningococcal (groups A, C, Y and W-135) oligosaccharide diphtheria CRM197 conjugate vaccine
Accession Number
DB10061
Description
Not Available
Type
Biotech
Groups
Approved
Biologic Classification
Vaccines
Other vaccines
Synonyms
Not Available

Pharmacology

Indication
Not Available
Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half-life
Not Available
Clearance
Not Available
Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Products

Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
Menjugate LiquidMeningococcal (groups A, C, Y and W-135) oligosaccharide diphtheria CRM197 conjugate vaccine (25 mcg/0.5mL) + Meningococcal polysaccharide vaccine group C (10 mcg/0.5mL)SuspensionIntramuscularGlaxosmithkline Inc2015-10-07Not applicableCanada
MenveoMeningococcal (groups A, C, Y and W-135) oligosaccharide diphtheria CRM197 conjugate vaccine (3.3-33.3 mcg/0.5mL) + Meningococcal polysaccharide vaccine group A (10 mcg/0.5mL) + Meningococcal polysaccharide vaccine group C (5 mcg/0.5mL) + Meningococcal polysaccharide vaccine group W-135 (5 mcg/0.5mL) + Meningococcal polysaccharide vaccine group Y (5 mcg/0.5mL)Powder, for solution; SolutionIntramuscularGlaxosmithkline Inc2010-07-29Not applicableCanada

Categories

Drug Categories
Not Available
Classification
Not classified

Chemical Identifiers

UNII
Not Available
CAS number
Not Available

References

General References
Not Available
Not Available

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4Active Not RecruitingPreventionPapillomavirus Infections1
4CompletedBasic ScienceBloodstream Infections / Meningitis / Meningococcal Disease1
4CompletedPreventionDiphtheria / Meningococcal / Pertussis Diseases / Streptococcal / Tetanus1
4CompletedPreventionMeningococcal Disease1
4CompletedTreatmentImmunizations / Meningitis / Pertussis / Preventive Immunization; Meningitis1
4RecruitingOtherHuman Immunodeficiency Virus (HIV) Infections / Meningococcal Meningitis1
4RecruitingOtherMeningococcal Meningitis1
4RecruitingPreventionMeningococcal Disease, Invasive1
3CompletedPreventionBloodstream Infections / Meningitis1
3CompletedPreventionMeningitis / Meningococcal Infections / Meningococcal Meningitis1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
SuspensionIntramuscular
Powder, for solution; solutionIntramuscular
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Drug created on November 30, 2015 14:23 / Updated on June 12, 2020 10:52

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates